 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright reaffirmed their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD  Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a...

Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright

Clearside Biomedical, Inc. (NASDAQ:CLSD  Free Report)  Wedbush lifted their FY2023 EPS estimates for shares of Clearside Biomedical in a research note issued on Tuesday, November 14th...

Clearside Biomedical, Inc. Expected to Earn FY2023 Earnings of ($0.60) Per Share (NASDAQ:CLSD)

Clearside Biomedical, Inc. (NASDAQ:CLSD  Free Report)  Investment analysts at HC Wainwright upped their FY2023 earnings per share (EPS) estimates for shares of Clearside Biomedical in a...

FY2023 Earnings Estimate for Clearside Biomedical, Inc. (NASDAQ:CLSD) Issued By HC Wainwright

Clearside Biomedical (NASDAQ:CLSD  Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, topping the consensus...

Clearside Biomedical (NASDAQ:CLSD) Issues Quarterly  Earnings Results

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcellx Inc (ACLX Research Report), Clearside Biom...

Analysts' Top Healthcare Picks: Arcellx Inc (ACLX), Clearside Biomedical (CLSD)

JMP Securities analyst Jonathan Wolleben has reiterated their bullish stance on CLSD stock, giving a Buy rating on November 6. Jonathan Wolleben ha...

Clearside Biomedical Earns Buy Rating Amid Successful Clinical Trials and Promising Partnerships: An Analysis by Jonathan Wolleben

- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside's Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...

Clearside Biomedical Announces Third Quarter 2023  Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Analysts at StockNews.com initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD  Get Free Report) in a research note issued on Wednesday. The brokerage set a sell&#8221...

Clearside Biomedical (NASDAQ:CLSD) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD  Get Free Report) in a report released on Wednesday. The firm set a sell rating on the...

Clearside Biomedical (NASDAQ:CLSD) Earns Sell Rating from Analysts at StockNews.com

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Watchers	4,930
52-Wk Low	$0.6501
52-Wk High	$1.82

Market Cap	$69.9M
Volume (M)	399,876.00
52-Wk High	$1.82
52-Wk Low	$0.6501

CLSD Clearside Biomedical Inc

About

Feed

News

Sentiment

Earnings

Fundamentals